Find Cabozantinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184
Molecular Formula
C32H30FN3O10
Molecular Weight
635.6  g/mol
InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
FDA UNII
DR7ST46X58

Cabozantinib
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.
1 2D Structure

Cabozantinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
2.1.2 InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
2.1.3 InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
2.1.4 Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O
2.1.5 Isomeric SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
DR7ST46X58
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 907351

2. Bms-907351

3. Bms907351

4. Cabozantinib

5. Cometriq

6. Xl 184

7. Xl-184

8. Xl184 Cpd

2.3.2 Depositor-Supplied Synonyms

1. 1140909-48-3

2. Cabozantinib Malate

3. Cabozantinib (s)-malate

4. Cabometyx

5. Cabozantinib Malate (xl184)

6. Xl184

7. Cabozantinib (s-malate)

8. Cometriq

9. Cabozantinib S-malate [usan]

10. Dr7st46x58

11. Bms907351

12. Chebi:72319

13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

14. Cabometyx (tn)

15. Cometriq (tn)

16. Cabozantinib Malate (jan)

17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid

18. Cabozantinib S-malate (usan)

19. Cabozantinib Malate [jan]

20. Unii-dr7st46x58

21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

23. Xl184 Malate

24. Cabozantinib L-malate

25. Bms907351 Malate

26. Xl184(cabozantinib Malate)

27. Mls006010951

28. Chembl2103868

29. Dtxsid60915949

30. Ex-a2819

31. Mfcd20923480

32. S4001

33. 1140909-48-3 (malate)

34. Akos025401945

35. Cabozantinib S-malate [who-dd]

36. Ccg-270301

37. Cs-0201

38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor

39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

40. Ac-27471

41. As-75255

42. Hy-12044

43. Smr004702755

44. Cabozantinib S-malate [orange Book]

45. Sw218093-2

46. D10095

47. Q27139901

48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)

52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt

53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)

54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate

2.4 Create Date
2008-12-22
3 Chemical and Physical Properties
Molecular Weight 635.6 g/mol
Molecular Formula C32H30FN3O10
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count12
Rotatable Bond Count11
Exact Mass635.19152232 g/mol
Monoisotopic Mass635.19152232 g/mol
Topological Polar Surface Area194 Ų
Heavy Atom Count46
Formal Charge0
Complexity924
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

* Renal Cell Carcinoma (RCC):

Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):

- in treatment-nave adults with intermediate or poor risk,

- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

* Hepatocellular Carcinoma (HCC):

Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX07


API SUPPLIERS

read-more
read-more

01

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WCInactive-api NDC arrow-down KDMF arrow-down VMF Others AUDIT arrow-down
Dr Reddy Company Banner

02

Granules India Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Granules India

03

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

04

Tagoor Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Tagoor Laboratories

05

Sichuan Qingmu Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothQingmu Pharma: Patients first, FDA/CEP/US-DMF/US-VMF/ASMF APIs for Humans & Vets in 100+ countries.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

06

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WCInactive-api NDC KDMF VMF Others AUDIT arrow-down
Dr Reddy Company Banner

07

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Dr Reddy Company Banner

08

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International
Not Confirmed
arrow

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International
Not Confirmed
arrow

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioProcess International
Not Confirmed
arrow

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioProcess International
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39141

Submission : 2023-12-01

Status : Active

Type : II

Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 38207

Submission : 2023-03-31

Status : Active

Type : II

Dr Reddy Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39274

Submission : 2023-12-29

Status : Active

Type : II

Dr Reddy Company Banner

04

Biocon Ltd

India

USDMF

arrow
Natural Products Expo
Not Confirmed

04

Biocon Ltd

India
arrow
Natural Products Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-12-06

Pay. Date : 2023-03-08

DMF Number : 38057

Submission : 2023-09-28

Status : Active

Type : II

blank

05

Natural Products Expo
Not Confirmed

05

Natural Products Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-06-25

Pay. Date : 2019-04-22

DMF Number : 33137

Submission : 2018-09-01

Status : Active

Type : II

blank

06

Natural Products Expo
Not Confirmed

06

Natural Products Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2017-06-08

Pay. Date : 2017-05-22

DMF Number : 31522

Submission : 2017-03-30

Status : Active

Type : II

blank

07

Natco Pharma Ltd

India

USDMF

arrow
Natural Products Expo
Not Confirmed

07

Natural Products Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-03-23

Pay. Date : 2022-02-28

DMF Number : 36509

Submission : 2022-02-28

Status : Active

Type : II

blank

08

Natural Products Expo
Not Confirmed

08

Natural Products Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39785

Submission : 2024-03-26

Status : Active

Type : II

blank

09

Natural Products Expo
Not Confirmed

09

Natural Products Expo
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39757

Submission : 2024-03-22

Status : Active

Type : II

blank

10

Natural Products Expo
Not Confirmed

10

Natural Products Expo
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-12-17

Pay. Date : 2019-10-11

DMF Number : 34201

Submission : 2019-11-06

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Cabozantinib S-Malate IH

Date of Issue : 2022-07-28

Valid Till : 2025-11-30

Written Confirmation Number : WC-0390

Address of the Firm : Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District -532409, Andhr...

Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Cabozantinib HCl IH

Date of Issue : 2022-07-28

Valid Till : 2025-11-30

Written Confirmation Number : WC-0390

Address of the Firm : Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam District -532409, Andhr...

Dr Reddy Company Banner

03

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Cabozantinib S-Malate IH

Date of Issue : 2025-12-03

Valid Till : 2028-04-14

Written Confirmation Number : WC-0340

Address of the Firm : R.S No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Va...

blank

04

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Cabozantinib (S) Malate IH

Date of Issue : 2022-09-30

Valid Till : 2025-04-14

Written Confirmation Number : WC-340n

Address of the Firm : RS No: 578, Near Effluent Channel, at & Post: Luna, Taluka: Padra, District: Vad...

blank

05

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Cabozantinib S-Malate IH

Date of Issue : 2025-09-19

Valid Till : 2028-05-05

Written Confirmation Number : WC-0349

Address of the Firm : Unit-II, Sy. Nos. 50, 53, 53/A, 54 & 54/A,Kardanur (Village), Patancheru (Mandal...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Cabozantinib (S)-malate

Registrant Name : Pamirae Co., Ltd.

Registration Date : 2025-04-04

Registration Number : Su574-29-ND

Manufacturer Name : Dr.Reddy's Laboratories Limi...

Manufacturer Address : CTO-SEZ Process Unit-01 Sector No’s. 28 to 34, 36 to 37, 40, 50 to 53 & 03, Survey ...

Dr Reddy Company Banner

02

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Cabozantinib (S)-malate

Registrant Name : Aging Life Science Co., Ltd.

Registration Date : 2023-05-19

Registration Number : Su434-54-ND

Manufacturer Name : MSN Laboratories Private Lim...

Manufacturer Address : Unit-II, Sy. No. 50, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Te...

blank

03

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Cabozantinib (S)-malate

Registrant Name : Ipsen Korea Co., Ltd.

Registration Date : 2019-04-26

Registration Number : Su183-2-ND

Manufacturer Name : Piramal Healthcare Canada Lt...

Manufacturer Address : 110 Industrial Parkway North Aurora, Ontario, Canada, L4G 3H4

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

CABOZANTINIB

NDC Package Code : 71796-059

Start Marketing Date : 2023-03-31

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Dr Reddy Company Banner

02

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 72804-0003

Start Marketing Date : 2024-12-03

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (25kg/25kg)

Marketing Category : BULK INGREDIENT

blank

03

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB

NDC Package Code : 54893-0130

Start Marketing Date : 2025-06-25

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB

NDC Package Code : 54893-0512

Start Marketing Date : 2024-09-30

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 54893-0058

Start Marketing Date : 2017-02-06

End Marketing Date : 2027-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 55679-116

Start Marketing Date : 2012-11-15

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 83137-0002

Start Marketing Date : 2023-02-01

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 59057-013

Start Marketing Date : 2022-08-31

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

BioProcess International US West
Not Confirmed
arrow
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB

NDC Package Code : 59057-019

Start Marketing Date : 2024-09-02

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

STERLING SPA

Italy
BioProcess International US West
Not Confirmed
arrow

STERLING SPA

Italy
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB

NDC Package Code : 64918-1924

Start Marketing Date : 2023-05-12

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Cabozantinib

About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...

Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfolio that provides high-quality, low-cost APIs to leading pharma companies in 80+ countries. It has 8 USFDA-inspected facilities – 6 in India & 1 each in Mexico & the UK & are inspected by international regulatory authorities on a regular basis. Its facilities are supplemented by formulation facilities that provide a wide range of dosage forms. Product(s) under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act and not for commercial sale
Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content

Cabozantinib

About the Company : Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the ...

Granules is a fast-growing, vertically integrated pharma company based in Hyderabad, committed to operational excellence, quality, and customer service. It manufactures across the entire value chain- APIs, Formulation Intermediates, & Formulations. With 11 facilities (8 in India, 2 in the US and 1 in Europe) approved by US FDA, EDQM, EU GMP, WHO GMP, & more, its products reach 300+ customers in 80+ countries. Granules has offices in India, the US, & Europe ensuring a strong global presence. Products listed herein may not be available for commercial use in countries where any relevant third-party intellectual property is in force.
Granules India

03

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Cabozantinib

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulation, analytical method development and testing, custom API synthesis, regulatory support, and commercial manufacturing. Supported by a network of over 300 accredited cGMP manufacturing partners and more than 100,000 sq. ft. of FDA-inspected cGMP manufacturing and warehouse space, LGM delivers secure, end-to-end solutions across multiple dosage forms. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
LGM Pharma CB

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Flag India
Digital Content Digital Content

Cabozantinib

About the Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-growth therapeutic ar...

Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-growth therapeutic areas. The company emphasizes affordability, quality, and timely delivery, and also offers end-to-end CDMO services. Headquartered in Hyderabad, Tagoor Labs serves branded and generic pharmaceutical companies worldwide, with integrated functions covering R&D, manufacturing, quality, regulatory affairs, supply chain, marketing, and warehousing. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Tagoor Laboratories

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothQingmu Pharma: Patients first, FDA/CEP/US-DMF/US-VMF/ASMF APIs for Humans & Vets in 100+ countries.

Flag China
Digital Content Digital Content

Cabozantinib Malate

About the Company : Sichuan Qingmu Pharmaceutical is an innovation-driven company specializing in generic APIs, advanced intermediates, and CDMO/CMO services for small-molecule drugs. Approved by US F...

Sichuan Qingmu Pharmaceutical is an innovation-driven company specializing in generic APIs, advanced intermediates, and CDMO/CMO services for small-molecule drugs. Approved by US FDA, Korea MFDS, and China NMPA, Qingmu supports global clients from early development to commercial supply, maintaining international quality standards. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

06

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Cabozantinib

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

07

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Cabozantinib

About the Company : Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is de...

Baran Chemical and Pharmaceutical Company operates as part of the DAKPHA Holding conglomerate. This conglomerate, driven by dedicated experts and state-of-the-art technology, is dedicated to advancing the pharmaceutical raw materials sector, producing diverse medical formulations, and enhancing public health by fulfilling community needs. Among its affiliated companies are "Danesh Pharmaceutical Development" and "Alborz Pharmed".
blank

08

Biocon

India
Natural Products Expo
Not Confirmed
arrow

Biocon

India
arrow
Natural Products Expo
Not Confirmed

Cabozantinib

About the Company : The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are Ind...

The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.
blank

09

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Cabozantinib

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance. Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 1986.
blank

10

Natural Products Expo
Not Confirmed
arrow
arrow
Natural Products Expo
Not Confirmed

Cabozantinib

About the Company : We are a world class innovation driven specialty pharmaceutical company with integrated Research, Development, Manufacturing and Marketing of Quality affordable medicines for a Hea...

We are a world class innovation driven specialty pharmaceutical company with integrated Research, Development, Manufacturing and Marketing of Quality affordable medicines for a Healthier Tomorrow. We always strive to focus on area of unmet medical need and leverages our expertise to bring in solutions that improve people’s health better around the world. We are committed to expand the horizons of healthcare by embracing new technologies, touching millions of lives with good health & partnering for a better tomorrow.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694629800,"product":"CABOZANTINIB (S)-MALATE (FORM-S)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC","customerCountry":"CANADA","quantity":"0.75","actualQuantity":"0.75","unit":"KGS","unitRateFc":"35000","totalValueFC":"25997.4","currency":"USD","unitRateINR":2877333.3333333335,"date":"14-Sep-2023","totalValueINR":"2158000","totalValueInUsd":"25997.4","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"3927575","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697653800,"product":"CABOZANTINIB (S) MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"UNDISCLOSED","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.60","actualQuantity":"1.6","unit":"KGS","unitRateFc":"14850","totalValueFC":"23453.3","currency":"USD","unitRateINR":1220000,"date":"19-Oct-2023","totalValueINR":"1952000","totalValueInUsd":"23453.3","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"4771140","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703356200,"product":"CABOZANTINIB HCL IH (MICRONIZED)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR REDDY'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"BASEL","customer":"DR REDDY'S LABORATORIES S A","customerCountry":"SWITZERLAND","quantity":"23.00","actualQuantity":"23","unit":"KGS","unitRateFc":"25165.3","totalValueFC":"575025.7","currency":"USD","unitRateINR":2081171.9130434783,"date":"24-Dec-2023","totalValueINR":"47866954","totalValueInUsd":"575025.7","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29141990","bill_no":"4000847","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Micronized","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1723487400,"product":"CABOZANTINIB(S)-MALATE(QTY:0.070 KGS)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TEL AVIV YAFO","customer":"TEVA PHARMACEUTICALS INDUSTRIES LTD","customerCountry":"ISRAEL","quantity":"0.07","actualQuantity":"0.07","unit":"KGS","unitRateFc":"17000","totalValueFC":"207.7","currency":"USD","unitRateINR":248849.99999999997,"date":"13-Aug-2024","totalValueINR":"17419.5","totalValueInUsd":"207.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"3171993","productDescription":"API","marketType":"","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728066600,"product":"CABOZANTINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GENVEON LLAC SANAYI VE TICARET AS","customerCountry":"TURKEY","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"20000","totalValueFC":"39512","currency":"USD","unitRateINR":1660028.5,"date":"05-Oct-2024","totalValueINR":"3320057","totalValueInUsd":"39512","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"4588959","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY CO DUBAI LLC","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"14850","totalValueFC":"14646.1","currency":"USD","unitRateINR":1235957.0900000001,"date":"12-Nov-2024","totalValueINR":"1235957.09","totalValueInUsd":"14646.1","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"5543338","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1732127400,"product":"CABOZANTINIB MALATE(AS PER INV & PKG)","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GENVEON ILA SAN VE TICAS","customerCountry":"TURKEY","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"10000","totalValueFC":"2924.1","currency":"USD","unitRateINR":822542.5,"date":"21-Nov-2024","totalValueINR":"246762.75","totalValueInUsd":"2924.1","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"5787335","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1733769000,"product":"CABOZANTINIB MALATE IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO LABS LTD","supplierCountry":"INDIA","foreign_port":"OSAKA","customer":"MEDISA SHINYAKU INC","customerCountry":"JAPAN","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"200000","totalValueFC":"59136","currency":"USD","unitRateINR":16749083.333333334,"date":"10-Dec-2024","totalValueINR":"5024725","totalValueInUsd":"59136","indian_port":"Hyderabad Air","hs_no":"29241900","bill_no":"6335971","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734287400,"product":"CABOZANTINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GENVEON LLAC SANAYI VE TICARET AS","customerCountry":"TURKEY","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"18000","totalValueFC":"213117.4","currency":"USD","unitRateINR":1509030.6666666667,"date":"16-Dec-2024","totalValueINR":"18108368","totalValueInUsd":"213117.4","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6477194","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734892200,"product":"CABOZANTINIB ( S ) -MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY CO DUBAI LLC","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.20","actualQuantity":"1.2","unit":"KGS","unitRateFc":"14850","totalValueFC":"17637.4","currency":"USD","unitRateINR":1248860.8333333335,"date":"23-Dec-2024","totalValueINR":"1498633","totalValueInUsd":"17637.4","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6680723","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734892200,"product":"CABOZANTINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"NOBEL ILAC SANAYII VE TICARET AS","customerCountry":"TURKEY","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"27500","totalValueFC":"6697.1","currency":"USD","unitRateINR":2276187,"date":"23-Dec-2024","totalValueINR":"569046.75","totalValueInUsd":"6697.1","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6696899","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1734978600,"product":"CABOZANTINIB MALATE","address":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA","city":"HYDERABAD,TELANGANA","supplier":"VALARY LAB PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"ORBIT SHIPPING SERVICES LLC","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"8000","totalValueFC":"2448.9","currency":"EURO","unitRateINR":693600,"date":"24-Dec-2024","totalValueINR":"208080","totalValueInUsd":"2448.9","indian_port":"Hyderabad Air","hs_no":"29329990","bill_no":"6737067","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"8-3-166\/7\/1, ERRAGADDA,,ERRAGADDA, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745260200,"product":"CABOZANTINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"GENVEON LLAC SANAYI VE TICARET AS","customerCountry":"TURKEY","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"18000","totalValueFC":"284966","currency":"USD","unitRateINR":1524600,"date":"22-Apr-2025","totalValueINR":"24393600","totalValueInUsd":"284966","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"1173302","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1752777000,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ZAGREB","customer":"PLIVA HRVATSKA DOO FTOZ","customerCountry":"CROATIA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"17000","totalValueFC":"168092.1","currency":"USD","unitRateINR":1446700,"date":"18-Jul-2025","totalValueINR":"14467000","totalValueInUsd":"168092.1","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"3675762","productDescription":"API","marketType":"REGULATED MARKET","country":"CROATIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753122600,"product":"CABOZANTINIB FUMARATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"NOBEL ILAC SANAYII VE TICARET AS","customerCountry":"TURKEY","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"27500","totalValueFC":"6679.7","currency":"USD","unitRateINR":2299562,"date":"22-Jul-2025","totalValueINR":"574890.5","totalValueInUsd":"6679.7","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"3783182","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q4","strtotime":1760725800,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"GADOR S A","customerCountry":"ARGENTINA","quantity":"4.20","actualQuantity":"4.2","unit":"KGS","unitRateFc":"13835.3","totalValueFC":"57206.9","currency":"USD","unitRateINR":1203666.7499999998,"date":"18-Oct-2025","totalValueINR":"5055400.35","totalValueInUsd":"57206.9","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"6292350","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
14-Sep-2023
18-Oct-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Belzutifan is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of von hippel-lindau disease.


Lead Product(s): Belzutifan,Palbociclib,Nivolumab,Lenvatinib,Cabozantinib

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 12, 2026

blank

01

Merck & Co

U.S.A
arrow
BioProcess International US West
Not Confirmed

Merck & Co

U.S.A
arrow
BioProcess International US West
Not Confirmed

Details : Belzutifan is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of von hippel-lindau disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 12, 2026

blank

Details:

Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.


Lead Product(s): Pumitamig,Ipilimumab,Cabozantinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated

Sponsor: BioNTech

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 19, 2025

blank

02

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Pumitamig is a antibody drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Carcinoma, Renal Cell.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

December 19, 2025

blank

Details:

The proceeds from the offering will be used to fund the clinical development of Casdatifan, a small molecule product targeting HIF-2α in the key focus area of cancer.


Lead Product(s): Casdatifan,Cabozantinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Leerink Partners | Goldman Sachs & Co | Cantor | Mizuho | Truist Securities

Deal Size: $250.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering October 30, 2025

blank

03

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Lead Product(s) : Casdatifan,Cabozantinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Leerink Partners | Goldman Sachs & Co | Cantor | Mizuho | Truist Securities

Deal Size : $250.0 million

Deal Type : Public Offering

Details : The proceeds from the offering will be used to fund the clinical development of Casdatifan, a small molecule product targeting HIF-2α in the key focus area of cancer.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 30, 2025

blank

Details:

The proceeds from the offering will be used to fund the clinical development of Casdatifan, a miscellaneous product targeting HIF-2-alpha in the key focus area of cancer.


Lead Product(s): Casdatifan,Cabozantinib

Therapeutic Area: Oncology Brand Name: AB521

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Leerink Partners | Goldman Sachs & Co

Deal Size: $234.5 million Upfront Cash: Undisclosed

Deal Type: Public Offering October 30, 2025

blank

04

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Lead Product(s) : Casdatifan,Cabozantinib

Therapeutic Area : Oncology

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Leerink Partners | Goldman Sachs & Co

Deal Size : $234.5 million

Deal Type : Public Offering

Details : The proceeds from the offering will be used to fund the clinical development of Casdatifan, a miscellaneous product targeting HIF-2-alpha in the key focus area of cancer.

Product Name : AB521

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 30, 2025

blank

Details:

The collaboration aims to advance Casdatifan for HIF-2α targeting in clear cell renal cell carcinoma.


Lead Product(s): Casdatifan,Cabozantinib

Therapeutic Area: Oncology Brand Name: AB521

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Taiho Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration October 19, 2025

blank

05

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : The collaboration aims to advance Casdatifan for HIF-2α targeting in clear cell renal cell carcinoma.

Product Name : AB521

Product Type : Miscellaneous

Upfront Cash : Undisclosed

October 19, 2025

blank
  • Development Update

Details:

Cabozantinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.


Lead Product(s): Cabozantinib,Nivolumab

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Exelixis

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 23, 2025

blank

06

MD Anderson Cancer Center

Country
arrow
BioProcess International US West
Not Confirmed

MD Anderson Cancer Center

Country
arrow
BioProcess International US West
Not Confirmed

Details : Cabozantinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Renal Cell.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 23, 2025

blank

Details:

Casdatifan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Renal Cell.


Lead Product(s): Casdatifan,Cabozantinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 10, 2025

blank

07

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Casdatifan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Renal Cell.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 10, 2025

blank

Details:

Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Neoplasms.


Lead Product(s): Nivolumab,Cabozantinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Antibody, Unconjugated

Sponsor: Gustave Roussy

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 18, 2025

blank

08

Ipsen

France
arrow
BioProcess International US West
Not Confirmed

Ipsen

France
arrow
BioProcess International US West
Not Confirmed

Details : Nivolumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Neoplasms.

Product Name : Undisclosed

Product Type : Antibody, Unconjugated

Upfront Cash : Inapplicable

April 18, 2025

blank

Details:

Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.


Lead Product(s): Cabozantinib,Inapplicable

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 26, 2025

blank

09

Exelixis

U.S.A
arrow
BioProcess International US West
Not Confirmed

Exelixis

U.S.A
arrow
BioProcess International US West
Not Confirmed

Details : Cabometyx (cabozantinib S-malate) is a oral TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.

Product Name : Cabometyx

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 26, 2025

blank

Details:

Abemaciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.


Lead Product(s): Abemaciclib,Cabozantinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Eli Lilly | Exelixis

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 19, 2025

blank

10

BioProcess International US West
Not Confirmed
BioProcess International US West
Not Confirmed

Details : Abemaciclib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 19, 2025

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 35654-56-9

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 849217-48-7

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 190728-25-7

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 113020-21-6

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

CAS Number : 598-10-7

End Use API : Cabozantinib

About The Company : Tagoor Laboratories, established in 2018 and part of the Tagoor Group, provides APIs, advanced intermediates, and key starting materials for critical and high-g...

Tagoor Laboratories

06

BioProcess International US West
Not Confirmed
arrow
BioProcess International US West
Not Confirmed
arrow

CAS Number : 35654-56-9

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

07

BioProcess International US West
Not Confirmed
arrow
BioProcess International US West
Not Confirmed
arrow

CAS Number : 598-10-7

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

08

BioProcess International US West
Not Confirmed
arrow
BioProcess International US West
Not Confirmed
arrow

CAS Number : 849217-48-7

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

09

BioProcess International US West
Not Confirmed
arrow
BioProcess International US West
Not Confirmed
arrow

CAS Number : 190728-25-7

End Use API : Cabozantinib

About The Company : Founded with a mission to transform strategic capital into specialty chemicals, Ami Group focuses on Agrochemicals, Cosmetics, and Polymers. Ami Organics Ltd. i...

blank

10

BioProcess International US West
Not Confirmed
arrow
BioProcess International US West
Not Confirmed
arrow

CAS Number : 35654-56-9

End Use API : Cabozantinib

About The Company : We are into manufacturing of bulk drug Intermediates and Active Pharmaceutical Ingredients (API). Our core competence is contract manufacturing for our clients ...

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Kabozantinib S-malate

Brand Name : Cabometyx

Dosage Form : Film Coated Tablet

Dosage Strength : 40mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Marketed

Registration Country : Norway

blank

02

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Kabozantinib S-malate

Brand Name : Cometriq

Dosage Form : Capsule

Dosage Strength : 20mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Not Marketed

Registration Country : Norway

blank

03

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form : Capsule

Dosage Strength : 20mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

04

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablet

Dosage Strength : 60mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

05

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film Coated Tablet

Dosage Strength : 40MG

Packaging :

Approval Date : 05-12-2016

Application Number : 1161136004

Regulatory Info : Authorized

Registration Country : Spain

blank

06

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film Coated Tablet

Dosage Strength : 20MG

Packaging :

Approval Date : 05-12-2016

Application Number : 1161136002

Regulatory Info : Authorized

Registration Country : Spain

blank

07

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Cabozantinib Malate

Brand Name : Cometriq

Dosage Form : Hard Capsules

Dosage Strength : 20mg; 80mg

Packaging :

Approval Date : 21-03-2014

Application Number : 28105211812

Regulatory Info : Prescription

Registration Country : Denmark

blank

08

Ipsen Pharma

France
BioProcess International US West
Not Confirmed
arrow

Ipsen Pharma

France
arrow
BioProcess International US West
Not Confirmed

Cabozantinib S-Malate

Brand Name : Cometriq

Dosage Form : Capsule

Dosage Strength : 20mg, 80mg

Packaging :

Approval Date : 21-03-2014

Application Number : 2.01E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

09

Teva Bv

Israel
BioProcess International US West
Not Confirmed
arrow

Teva Bv

Israel
arrow
BioProcess International US West
Not Confirmed

Cabozantinib Malate

Brand Name : Cabozantinib \"Teva\"

Dosage Form : Film Coated Tablet

Dosage Strength : 20mg

Packaging :

Approval Date : 24-06-2025

Application Number : 28106942223

Regulatory Info : Prescription

Registration Country : Denmark

blank

10

Teva Bv

Israel
BioProcess International US West
Not Confirmed
arrow

Teva Bv

Israel
arrow
BioProcess International US West
Not Confirmed

Cabozantinib Malate

Brand Name : Cabozantinib \"Teva\"

Dosage Form : Film Coated Tablet

Dosage Strength : 60mg

Packaging :

Approval Date : 24-06-2025

Application Number : 28106942423

Regulatory Info : Prescription

Registration Country : Denmark

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - EQ 20MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

DOSAGE - CAPSULE;ORAL - EQ 80MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Lubricants & Glidants

read-more
read-more

Granulation

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Empty Capsules

read-more
read-more

Co-Processed Excipients

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Taste Masking

read-more
read-more

Topical

read-more
read-more

Solubilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Coloring Agents

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
BioProcess International
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 8877776

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208692

Patent Use Code : U-3225

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-10-08

blank

02

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 11098015

Drug Substance Claim :

Drug Product Claim :

Application Number : 208692

Patent Use Code : U-3225

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-15

blank

03

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 12128039

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208692

Patent Use Code : U-2488

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-02-10

blank

04

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 12128039

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 208692

Patent Use Code : U-2488

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2032-02-10

blank

05

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 7579473

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 208692

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2026-08-14

blank

06

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 11091439

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 208692

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-15

blank

07

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 11098015

Drug Substance Claim :

Drug Product Claim :

Application Number : 208692

Patent Use Code : U-2488

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-15

blank

08

arrow
BioProcess International US West
Not Confirmed

EXELIXIS INC

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 11098015

Drug Substance Claim :

Drug Product Claim :

Application Number : 208692

Patent Use Code : U-1480

Delist Requested :

Patent Use Description : TREATMENT OF ADVANCED ...

Patent Expiration Date : 2030-01-15

blank

09

arrow
BioProcess International US West
Not Confirmed

EXELIXIS

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 8877776

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 203756

Patent Use Code : U-1617

Delist Requested :

Patent Use Description : METHOD OF TREATING MED...

Patent Expiration Date : 2030-10-08

blank

10

arrow
BioProcess International US West
Not Confirmed

EXELIXIS

U.S.A
arrow
BioProcess International US West
Not Confirmed

CABOZANTINIB S-MALATE

US Patent Number : 11091440

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 203756

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-01-15

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 1140909-48-3 / Cabozantinib API manufacturers, exporters & distributors?

Cabozantinib manufacturers, exporters & distributors 1

82

PharmaCompass offers a list of Cabozantinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabozantinib manufacturer or Cabozantinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabozantinib manufacturer or Cabozantinib supplier.

PharmaCompass also assists you with knowing the Cabozantinib API Price utilized in the formulation of products. Cabozantinib API Price is not always fixed or binding as the Cabozantinib Price is obtained through a variety of data sources. The Cabozantinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Cabozantinib

Synonyms

1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184

Cas Number

1140909-48-3

Unique Ingredient Identifier (UNII)

DR7ST46X58

About Cabozantinib

Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

Cabozantinib Manufacturers

A Cabozantinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib, including repackagers and relabelers. The FDA regulates Cabozantinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cabozantinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cabozantinib Suppliers

A Cabozantinib supplier is an individual or a company that provides Cabozantinib active pharmaceutical ingredient (API) or Cabozantinib finished formulations upon request. The Cabozantinib suppliers may include Cabozantinib API manufacturers, exporters, distributors and traders.

click here to find a list of Cabozantinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cabozantinib USDMF

A Cabozantinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib DMFs exist exist since differing nations have different regulations, such as Cabozantinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cabozantinib DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib USDMF includes data on Cabozantinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cabozantinib suppliers with USDMF on PharmaCompass.

Cabozantinib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Cabozantinib Drug Master File in Korea (Cabozantinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib. The MFDS reviews the Cabozantinib KDMF as part of the drug registration process and uses the information provided in the Cabozantinib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Cabozantinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Cabozantinib suppliers with KDMF on PharmaCompass.

Cabozantinib WC

A Cabozantinib written confirmation (Cabozantinib WC) is an official document issued by a regulatory agency to a Cabozantinib manufacturer, verifying that the manufacturing facility of a Cabozantinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib APIs or Cabozantinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib WC (written confirmation) as part of the regulatory process.

click here to find a list of Cabozantinib suppliers with Written Confirmation (WC) on PharmaCompass.

Cabozantinib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cabozantinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cabozantinib suppliers with NDC on PharmaCompass.

Cabozantinib GMP

Cabozantinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cabozantinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib GMP manufacturer or Cabozantinib GMP API supplier for your needs.

Cabozantinib CoA

A Cabozantinib CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib's compliance with Cabozantinib specifications and serves as a tool for batch-level quality control.

Cabozantinib CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cabozantinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib EP), Cabozantinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty